Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Geoffrey Block
Clinical Professor, Medicine
Medicine
Overview
Research
More
Collaboration
(11)
Wahid Wassef
Mutual work: 1 Grant
Collaboration Details
Maria Fotinos
Mutual work: 1 Grant
Collaboration Details
Bernard Futscher
Mutual work: 1 Grant
Collaboration Details
Denise Roe
Mutual work: 1 Grant
Collaboration Details
Mark Nelson
Mutual work: 1 Grant
Collaboration Details
Page 1 of 3
Previous page
Next page
Grants
(8)
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency?associated Liver Disease With Metavir
Active
·
2023
·
$10.9M / $1.6M
·
External
Principal Investigator (PI)
clinical trial,
liver disease,
alpha-1 antitrypsin,
treatment,
safety
TRANSFORM: A 52-week, Randomized, Placebo-controlled, Double-blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52-week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevate
Active
·
2023
·
$4.5M / $641.6K
·
External
Principal Investigator (PI)
clinical trial,
drug therapy,
liver disease,
biomarker,
immunology
Success, Health, Innovation, and Equity-Arizona Research Center (SHINE-ARC)
Active
·
2022
·
$734.4K / $4.1M
·
External
Co-Investigator (COI)
health,
equity,
innovation,
research,
center
DNA methylation, Liquid Biopsy, and Pancreatic Cancer
Active
·
2022
·
$78.2K / $391.1K
·
External
Co-Investigator (COI)
dna methylation,
liquid biopsy,
pancreatic cancer
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects with Primary Biliary Cholangitis
Active
·
2022
·
$1.6M / $258.5K
·
External
Principal Investigator (PI)
clinical trials,
liver disease,
drug efficacy,
safety evaluation,
therapeutic intervention
Page 1 of 2
Previous page
Next page
Publications
(29)
Recent
Measuring Liver Disease Knowledge in Individuals with Cirrhosis
2022
NON-ALCOHOLIC FATTY LIVER DISEASE: DO NON-INVASIVE FIBROSIS SCORES STILL HAVE A ROLE IN PREDICTING EARLY STAGE HEPATIC FIBROSIS?
2022
Histologic Risk Factors for Steatohepatitis
2021
NON-ALCOHOLIC FATTY LIVER DISEASE: DO NON-INVASIVE FIBROSIS SCORES STILL HAVE A ROLE IN PREDICTING EARLY STAGE HEPATIC FIBROSIS? Submission Type: AASLD Oral or Poster Submissions
2021
Quality of Life in Cirrhotic Patients post hospital admission
2020
COVID-19 Prevalence and complications in chronic liver disease and liver transplant
2020
Total pancreatectomy and islet autotransplantation in chronic pancreatitis: recommendations from PancreasFest
2013
D-galactosamine based canine acute liver failure model
2002
Procreation for Donation: The Moral and Political Permissibility of “Having a Child to Save a Child”
2001
Health problems in adolescents with alcohol use disorders: self-report, liver injury, and physical examination findings and correlates
2001